FindTrial
Sign In

treatment group:Chimeric Antigen Receptor T-Cell Immunotherapy

4 trials

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hebei Yanda Ludaopei Hospital, Department of Hematology, Changzheng Hospital, The Second Military Medical University.

Conditions

CD30-positive lymphoproliferative disordersMultiple Myelomarefractory or relapsed B acute lymphoblastic leukemiarelapsed or refractory B acute lymphoblastic leukemia

Early Phase 1

An open label, single center, single arm clinical study for infusion of anti-CD30 CAR-T therapy following autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk CD30-positive lymphoproliferative disorders
RecruitingChiCTR2100053662
Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD30-positive lymphoproliferative disorders
Start: 2019-06-01Updated: 2022-10-17

Phase 1

Autologous anti-CD19 chimeric antigen receptor T cells treat relapsed or refractory B acute lymphoblastic leukemia
RecruitingChiCTR-IIh-16008711
Hebei Yanda Ludaopei Hospitalrelapsed or refractory B acute lymphoblastic leukemia
Start: 2016-06-02Updated: 2017-04-18

Phase 2

Phase II study of autologous anti-CD19 chimeric antigen receptor T cells treating refractory and relapsed B acute lymphoblastic leukemia
RecruitingChiCTR-OIC-16009259
Hebei Yanda Ludaopei Hospitalrefractory or relapsed B acute lymphoblastic leukemia
Start: 2016-09-23Updated: 2017-04-18

Unknown Phase

Clinical investigation on the efficacy and safety of Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in relapsed and refractory multiply myeloma
Active, not recruitingChiCTR-INh-16008198
Department of Hematology, Changzheng Hospital, The Second Military Medical University.Multiple Myeloma
Start: 2016-04-20Updated: 2017-04-18

Related Papers

CD72 as a complementary B-lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR-T therapy in R/R B-ALL.
2026-08-03
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Experimental Hematology and Oncology2022-10-1715 citations
Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30<sup>+</sup> lymphoma.
Journal of Clinical Oncology2022-06-011 citations
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy
Leukemia & lymphoma/Leukemia and lymphoma2021-10-2116 citations